TITLE

TRACLEER PROMISING AS DIGITAL ULCER TREATMENT

PUB. DATE
October 2002
SOURCE
Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Looks at the preliminary results of Actelion Limited's evaluation of the efficacy and safety of TracleerTM in the treatment of digital ulcerations in scleroderma patients.
ACCESSION #
7464138

 

Related Articles

  • Actelion, GSK Ink $3.2B Deal with Almorexant as Centerpiece. Sheridan, Cormac // BioWorld Today;7/15/2008, Vol. 19 Issue 136, p1 

    The article reports on the strategic collaboration reached by Actelion Ltd. with GlaxoSmithKline (GSK) plc for the development of orexin antagonists in 2008. Particular focus is given on the clinical trials on the lead antagonist, almorexant, by Actelion. Information on the lead orexin...

  • Actelion Advances Clazosentan Into Phase III Vasospasm Study. Sheridan, Cormac // BioWorld International;11/14/2007, Vol. 12 Issue 46, p1 

    The article reports on the decision of Actelion Ltd. to move the endothelin receptor antagonist clazosentan (Pivlaz) into a pivotal Phase III trial to evaluate its effect on reducing vasospasm-related morbidity and mortality in patients at risk of vasospasm following aneurysmal subarachnoid...

  • Almorexant Showed Efficacy, but Raised Flags.  // Bioworld Week;12/28/2009, Vol. 17 Issue 52, p3 

    The article reports on the Phase III trial of Actelion Ltd.'s sleep medicine almorexant which reported efficacy but needs certain safety observations in Switzerland. It states that almorexant met its primary endpoint in the RESTORA Phase 1 trial with superiority of the dual orexin receptor...

  • Actelion Moves Oral Prostacyclin Analogue into Phase III Studies. Sheridan, Cormac // BioWorld International;7/22/2009, Vol. 14 Issue 29, p1 

    The article reports on the plans of Actelion AG of Allschwill, Switzerland to start its Phase III morbidity/mortality trial of its oral prostacyclin receptor agonist in pulmonary arterial hypertension after it released a positive data from its Phase IIa trial. This vasodilatory compound was...

  • Actelion Rises on Safety Data Despite Macitentan Miss in IPF. Sheridan, Cormac // BioWorld Today;8/30/2011, Vol. 22 Issue 168, p1 

    The article reports on the efficacy of the Macitentan drug in patients with idiopathic pulmonary fibrosis, as presented by manufacturer Actelion Pharmaceuticals Ltd. in August 2011. It mentions the failure of the drug, an endothelin receptor antagonist (ERA), to achieve the primary endpoint in...

  • Pirfenidone Panel, Tracleer Data to Start IPF Pot Boiling. Osborne, Randy // BioWorld Insight;2/8/2010, Vol. 18 Issue 6, p1 

    The article reports on the implications of Actelion Ltd.'s success in the phase III clinical trial of its Tracleer drug for idiopathic pulmonary fibrosis (IPF) for the pivotal results of InterMune Inc.'s clinical trial of its pirfenidone compound in the U.S. Robert Baltera of Amira...

  • Actelion Shares Fall on Clazosentan Phase III Miss. Sheridan, Cormac // BioWorld Today;9/28/2010, Vol. 21 Issue 187, p1 

    the article reports on the failure of a Phase III pivotal trial of clazosentan to reach primary endpoint in aneurysmal subarachnoid hemorrhage (aSAH) patients, which led to the decline of the shares of Actelion Pharmaceuticals Ltd. by about 8 percent on September 27, 2010. The aim of the trial...

  • Actelion Rises on Safety Data Despite Macitentan Miss in IPF. Sheridan, Cormac // BioWorld International;8/31/2011, Vol. 16 Issue 35, p1 

    The article reports on the optimism of Actelion Pharmaceuticals Ltd. despite the failure of its drug macitentan to demonstrate efficacy in idiopathic pulmonary fibrosis (IPF). The company believes that the drug's favorable safety profile could augur well for an ongoing Phase III trial in...

  • Actelion Shares Fall on Clazosentan Phase III Miss. Sheridan, Cormac // BioWorld International;9/29/2010, Vol. 15 Issue 38, p1 

    The article reports on an 8% decline in shares in Actelion Pharmaceuticals Ltd. after the results of a Phase III trial of clazosentan was disclosed. The company reported that clazosentan failed to reach the primary endpoint in patients who had undergone surgical clipping to treat a form of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics